Onyx leads declines in biotech stocks
May 19, 2011 at 11:19 AM EDT
Shares of Onyx Pharmaceuticals are falling after it released data from a Phase II study for its drug Nexavar in the treatment of breast cancer.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.